Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy

Thyroid. 2023 Sep;33(9):1119-1123. doi: 10.1089/thy.2022.0707. Epub 2023 Sep 1.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma*
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Iodine Radioisotopes / therapeutic use
  • Iodine* / therapeutic use
  • Thyroid Neoplasms* / drug therapy
  • Thyroid Neoplasms* / radiotherapy

Substances

  • Iodine Radioisotopes
  • Iodine
  • Antineoplastic Agents